A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Liraglutide (Saxenda)

Liraglutide lowers blood sugar and promotes weight loss by mimicking the GLP-1 hormone, used in type 2 diabetes.

First FDA approval2010-01-25
Generic availableYes · 6 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$383.1M in CY2024 Part D spend457K claims · 170K beneficiaries · 329 plans surveyed

Lowest NADAC
$39.43/unit
12 NDCs benchmarked, lowest of all strengths.
Average NADAC
$55.46
Across all dosage forms in distribution.
Highest NADAC
$87.86
Range is tight.
Plans with PA
97 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Liraglutide used for?

Liraglutide lowers blood sugar and promotes weight loss by mimicking the GLP-1 hormone, used in type 2 diabetes.

Is there a generic for Liraglutide?

Yes. 8 ANDAs filed at FDA, 6 generic manufacturers currently shipping.

How much does my plan pay for Liraglutide?

Across 329 Part D plans, Liraglutide averages $55.46/unit (NADAC). Lowest available: $39.43/unit. Highest in distribution: $87.86/unit.

Is Liraglutide on the FDA shortage list?

Yes. Liraglutide is currently listed as an active FDA shortage.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

GLP-1 Receptor Agonist3 alternatives in D1
01
Dulaglutide
Brand: TRULICITY
$487.63Lowest NADAC
0Generic mfrs
$7.87BCY24 Part D spend
Compare →
02
Exenatide
Brand: Byetta
$299.50Lowest NADAC
0Generic mfrs
$18.7MCY24 Part D spend
Compare →
03
Semaglutide
Brand: OZEMPIC
$33.16Lowest NADAC
0Generic mfrs
$24.17BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (12 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.